Morning Market Losers
Geron (NASDAQ: GERN) fell 50.69% to $1.43 at 9:52 am. Geron announced that, on the basis of an unplanned interim analysis, it is discontinuing its randomized Phase 2 study of imetelstat in metastatic HER2-negative breast cancer.
Nordion (NYSE: NDZ) shares dipped 39.06% to $6.49. Nordion announced its plans to suspend its quarterly dividend after an arbitration loss.
Zalicus (NASDAQ: ZLCS) shares lost 26.62% to $1.02. Zalicus announced top line results from its Phase 2b clinical trial of Synavive® in rheumatoid arthritis.
Synergy Pharmaceuticals (NASDAQ: SGYPU) dropped 25.52% to $11.15. Synergy Pharmaceuticals' 52-week trading range is $9.80-$15.88.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.